54 Results for "

pumilacidin

" in MedChemExpress (MCE) Product Catalog:
Products (54)

54 Results for "pumilacidin" in MCE Product Catalog:

40
40 Publications Verification
Cat. No.: HY-P0014
CAS No.: 204656-20-2
Target:  

GCGR GLP Receptor

Research Areas:  

Metabolic Disease Cancer

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.
40
40 Publications Verification
Cat. No.: HY-P0014B
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .
3
3 Cited Publications
Cat. No.: HY-P3462
CAS No.: 1415456-99-3
Target:  

CGRP Receptor

Research Areas:  

Metabolic Disease

Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .
3
3 Cited Publications
Cat. No.: HY-P3462A
Target:  

CGRP Receptor

Research Areas:  

Metabolic Disease

Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .
1
1 Cited Publications
Cat. No.: HY-P2231
CAS No.: 1686108-82-6
Synonyms: MEDI0382
Target:  

GCGR

Research Areas:  

Metabolic Disease

Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
1
1 Cited Publications
Cat. No.: HY-P2231A
Synonyms: MEDI0382 acetate
Target:  

GCGR

Research Areas:  

Metabolic Disease

Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
1
1 Cited Publications
Cat. No.: HY-P3291
CAS No.: 2296814-85-0
Synonyms: ZP7570
Target:  

GCGR

Research Areas:  

Metabolic Disease

Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .
1
1 Cited Publications
Cat. No.: HY-P10218
CAS No.: 479482-23-0
Target:  

MARCKS PKC

Research Areas:  

Inflammation/Immunology Cancer

MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
1
1 Cited Publications
Cat. No.: HY-P10218A
Target:  

MARCKS PKC

Research Areas:  

Inflammation/Immunology Cancer

MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
1
1 Cited Publications
Cat. No.: HY-P10869
dCNP binds to NPR-B/C receptor, activates cGMP signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses .
Cat. No.: HY-P10272
CAS No.: 1628323-80-7
Synonyms: PTG-300
Target:  

Ferroportin

Research Areas:  

Others

Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .
Cat. No.: HY-P0014S1
Research Areas:  

Others

Liraglutide- 13C6, 15 tetraTFA is the 13C and 15N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .
Cat. No.: HY-P10271
Synonyms: NNC0090-2746; MAR709; RO6811135
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC50 of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .
Cat. No.: HY-P10031
Target:  

GLP Receptor GCGR

Research Areas:  

Metabolic Disease

SAR441255 is a GLP-1R/GCGR/GIPR agonist, with human EC50 values of 1.03 pM, 1.01 pM, and 0.73 pM, respectively. SAR441255 stimulates receptor activity and drives cAMP accumulation. SAR441255 can be used for the research of type 2 diabetes, obesity .
Cat. No.: HY-P3143
CAS No.: 1629655-80-6
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .
Cat. No.: HY-P11273
CAS No.: 1610366-43-2
Synonyms: OK 101
Urcosimod (OK 101) is a lipid-coupled chemokine peptide, a ChemR23 G protein-coupled receptor agonist, which has been shown to have anti-inflammatory and analgesic activities. Urcosimod can be used for dry eye research .
Cat. No.: HY-153476
CAS No.: 2807481-02-1
Target:  

GCGR GLP Receptor

Research Areas:  

Inflammation/Immunology

GIP/GLP-1 dual receptor agonist-1 is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .
Cat. No.: HY-153476A
Target:  

GLP Receptor GCGR

Research Areas:  

Inflammation/Immunology

GIP/GLP-1 dual receptor agonist-1 sodium is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 sodium is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .
Cat. No.: HY-P11290
CAS No.: 1228015-10-8
Target:  

Melanocortin Receptor

Research Areas:  

Metabolic Disease

MC4-NN2-0453, a α-MSH analog, is a selective MC4R agonist. MC4-NN2-0453 can be used for obesity research .
Cat. No.: HY-P10341
CAS No.: 1345835-12-2
Target:  

GCGR

Research Areas:  

Metabolic Disease

ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .